Premium
Excision of pseudotumour in a patient with haemophilia A and inhibitor managed with recombinant factor VIIa
Author(s) -
Takedani H.,
Mikami S.,
Kawasaki N.,
Abe Y.,
Arai M.,
Naka H.,
Yoshioka A.
Publication year - 2004
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2004.00784.x
Subject(s) - medicine , recombinant factor viia , haemophilia , surgery , adverse effect , haemophilia a , recombinant dna , factor viia , bolus (digestion) , hemostasis , anesthesia , coagulation , tissue factor , biochemistry , chemistry , gene
Summary. We describe a patient with haemophilia A and factor VIII inhibitor who underwent surgical excision of a large pseudotumour in the left femoral region. Haemostasis was successfully maintained with bolus doses of recombinant factor VIIa at 2‐h intervals and anti‐fibrinolytic therapy, and the pseudotumour was removed. Subsequently, the dose interval was gradually prolonged to 8 h for a total of 18 days. Although a spontaneous haemorrhage was observed on postoperative day 8, haemostasis was achieved by reducing the dosage interval. No adverse event occurred during the course of treatment.